Skip to main content
Fig. 2 | Human Genomics

Fig. 2

From: Identification of drug repurposing candidates based on a miRNA-mediated drug and pathway network for cardiac hypertrophy and acute myocardial infarction

Fig. 2

The significantly dysregulated MGDTs in the cardiac hypertrophy and AMI networks. a The significantly dysregulated MGDTs in the cardiac hypertrophy network. b The significantly dysregulated MGDTs in the AMI network. c The numbers of nodes, edges, genes, miRNAs, and drugs in the cardiac hypertrophy and AMI networks. d Pie charts showing the percentages of significantly dysregulated MGDTs out of all MGDTs in the cardiac hypertrophy and AMI networks. e Venn diagram showing the common dysregulated MGDTs between the cardiac hypertrophy and AMI networks. f The common dysregulated MGDTs in the networks

Back to article page